Definitive Contract 75A50120C00171
Award Date
9/28/20
Potential Completion Date
6/1/28
Potential Value
$33M
Awardee
Invirsa, Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Sharing
Place of Performance
GRANDVIEW, OH 43212, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), part of the U.S. Department of Health and Human Services (HHS), to Venatorx Pharmaceuticals Inc., a biopharmaceutical company specializing in the discovery and development of novel anti-infective therapeutics. The contract, valued at $147,481,537.00, does not have a set-aside designation and was awarded as a definitive, cost-sharing contract. The work under this contract...
This federal contract award, valued at $330,136,246.14, was granted by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services, to 4J Therapeutics Inc., a self-certified small disadvantaged business. The contract's objective is to demonstrate the versatility and efficacy of 4J Therapeutics' programmable antiviral technology platform by assembling a preclinical package for LNA14, performing a Phase 1a...
This is a $167,067,962 definitive cost-sharing contract awarded to Venatorx Pharmaceuticals Inc. by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR). The contract, which does not have a set-aside designation, supports the advanced research and development of new antibiotics to treat drug-resistant gram-negative bacteria, including public health pathogens. This work aligns with BARDA's mission to develop medical countermeasures...
This is a $36,967,744.00 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Asell, LLC for the advanced development, validation, and FDA clearance of the CellRadX point-of-care biodosimetry system. The contract is not set-aside. This contract was awarded under a Broad Agency Announcement (BAA) solicitation from the Biomedical Advanced Research and Development Authority (BARDA) seeking proposals for the advanced...
The Department of Health and Human Services' Biomedical Advanced Research and Development Authority awarded a $269,952,453 firm fixed price definitive contract to Global Health Investment Corporation, a nonprofit organization. This contract establishes a public-private partnership through BARDA's other transaction authority to address gaps in pandemic preparedness and response. Specifically, the partnership will foster and accelerate medical countermeasure development using strategic venture...
This federal contract award was issued by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS). The contract, with a ceiling value of $11,399,982.00, was awarded to the prime contractor Battelle Memorial Institute (Battelle) to develop human-relevant small animal models of sulfur mustard toxicities.
The contract is a delivery order issued against the Biomedical Advanced Research and...
This federal contract award was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Inflammatix, Inc., a small disadvantaged business. The $749,999 firm fixed-price contract supports research and development for the Triverity cartridge, a diagnostic tool focused on infection severity and sepsis detection, under Area of Interest #2 of ASPR's Easy Broad Agency Announcement. The...
This is a $7,621,277 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Microbiotix, Inc., a clinical-stage biopharmaceutical company. The contract is for the development of phenoxyacetamide T3SS inhibitors as adjunctive agents to antibacterial therapy for multidrug-resistant Pseudomonas aeruginosa infections. This contract is not set aside for any specific...
The federal contract award HHSO100201000026C was issued by the Department of Health and Human Services (HHS) to Elusys Therapeutics Inc., a for-profit biomedical company, for advanced biomedical research and development. The $138,258,201.80 cost-plus-fixed-fee contract has an ultimate completion date of September 30, 2018. The contract is not designated as a set-aside. Elusys Therapeutics Inc. specializes in developing biomedical products and services, with a focus on advanced technology. The...
This is a $749,999.00 Firm Fixed Price contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Isola Therapeutics Inc. for research and development of endobronchial lavage (EBL) to prevent and treat lung damage from pulmonary chemical agents. The contract is part of the agency's "Redirect" program, which focuses on repurposing drugs in response to chemical threats. The contract does not have a set-aside designation and is...